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While next-generation sequencing has accelerated the discovery of human disease genes, progress has been largely limited to
the “low hanging fruit” of mutations with obvious exonic coding or canonical splice site impact. In contrast, the lack of high-
throughput, unbiased approaches for functional assessment of most noncoding variants has bottlenecked gene discovery.
We report the integration of transcriptome sequencing (RNA-seq), which surveys all mRNAs to reveal functional impacts of
variants at the transcription level, into the gene discovery framework for a unique human disease, microcephaly-micromelia
syndrome (MMS). MMS is an autosomal recessive condition described thus far in only a single First Nations population and
causes intrauterine growth restriction, severe microcephaly, craniofacial anomalies, skeletal dysplasia, and neonatal lethal-
ity. Linkage analysis of affected families, including a very large pedigree, identified a single locus on Chromosome 21 linked
to the disease (LOD > 9). Comprehensive genome sequencing did not reveal any pathogenic coding or canonical splicing
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mutations within the linkage region but identified several nonconserved noncoding variants. RNA-seq analysis detected
aberrant splicing in DONSON due to one of these noncoding variants, showing a causative role for DONSON disruption
in MMS. We show that DONSON is expressed in progenitor cells of embryonic human brain and other proliferating tissues,
is co-expressed with components of the DNA replication machinery, and that Donson is essential for early embryonic devel-
opment in mice as well, suggesting an essential conserved role for DONSON in the cell cycle. Our results demonstrate the
utility of integrating transcriptomics into the study of human genetic disease when DNA sequencing alone is not sufficient
to reveal the underlying pathogenic mutation.
[Supplemental material is available for this article.]
Noncodingmutations,whichaffect gene expression, regulation, or
splicing, are estimated to cause ∼15%–30% of human Mendelian
disease (Cartegni et al. 2002; Faustino and Cooper 2003; Lim
et al. 2011; Lewandowska 2013). This could, in fact, be an un-
derestimate since most genetic studies focus on coding regions
(the exome) and immediately adjacent intronic splice sites
whose effects are simpler to predict in silico using the amino
acid code and basic splicing consensus sequences (Cartegni et al.
2002; Faustino and Cooper 2003; Pagani and Baralle 2004;
Lopez-Bigas et al. 2005; Cooper and Shendure 2011; Lim et al.
2011; Lewandowska 2013). In contrast, noncoding variants are
harder to interpret due to the lack of a functional understanding
of most noncoding elements in the genome (Pagani and Baralle
2004; MacArthur et al. 2014). Therefore, even though most of
the genome and most variants identified by whole-genome se-
quencing are noncoding, noncoding variants causing Mendelian
disease are rarely identified before the affected gene has already
been implicated by codingmutations. Althoughmost gene regula-
tion occurs outside of the exome—in noncoding regions such as
promoters, enhancers, untranslated regions (UTRs), introns, and
intergenic regions—if a genetic disease is caused by a noncoding
mutation in a novel gene, it may not be possible to identify it
with DNA sequencing alone among the large background of other
noncoding variants. Furthermore, mutations in coding regions
may also affect gene expression and splicing in addition to the
protein sequence (Cartegni et al. 2002; Lopez-Bigas et al. 2005;
Lewandowska 2013), effects that cannot be detected by DNA se-
quencing alone. As a result, even while high-throughput DNA
sequencing technologies have led to remarkable progress in iden-
tifying mutations causing genetic diseases, important genetic dis-
orders remain unsolved in which this approach fails, presumably
because the pathogenic mutation is noncoding or is a coding re-
gion mutation affecting transcription.
Transcriptome sequencing (RNA-seq) has been key to reveal-
ing the complexity of gene regulation across cell types and states
by its ability to profile transcript levels as well as alternative splic-
ing patterns genome-wide (Pan et al. 2008; Wang et al. 2009; de
Klerk and ‘t Hoen 2015), processes largely dictated by the non-
coding genome. Nevertheless, transcriptome sequencing has not
been an integral part of the gene discovery framework of human
Mendelian disease studies. This might be because transcriptome
sequencing ideally requires RNA from the diseased tissues of affect-
ed individuals, which is not always available, and entails the added
cost and complexity of RNA sequencing and analysis relative to
DNA sequencing alone.
We aimed to test whether RNA-seq could discover, in one
experiment, a pathogenic noncoding mutation or transcription-
altering exonicmutation causing human disease, without needing
to test a large or unfeasible number of possible splicing or gene
regulation defects by traditional molecular biology methods. We
tested this approach by applying it to microcephaly-micromelia
syndrome (MMS), a condition for which we had highly significant
statistical linkage to a genetic locus but for which no obvious
pathogenic coding or splicing mutation had been found by DNA
sequencing.
MMS was first described in 1980 by Ives and Houston (Ives
and Houston 1980) in a First Nations population in northern
Saskatchewan in Canada. The syndrome’s main clinical features
are intrauterine growth restriction (IUGR), severe microcephaly,
craniofacial dysmorphism, and marked limb malformations.
Since the 1950s, an average of two pregnancies or births per year
have been diagnosed with MMS in this population and, with the
exception of two known children, all were stillborn or died within
the first week of life, mostly within 24 h of birth. No cases of MMS
have been identified outside of this First Nations population in
Saskatchewan.While the clinical phenotype ofMMS is distinctive,
the constellation of IUGR,microcephaly, and limb anomalies plac-
es MMS in the broad category of microcephalic primordial dwarf-
ism (MPD) syndromes, which have been associated with defects in
genes involved in genome replication, the DNA damage response,
and centrosome function (Klingseisen and Jackson 2011).
In this study, we sought to identify the genetic cause of MMS
using a combinedRNA-seq plus genome sequencing approach.We
took this approach as a proof of principle to gauge the advan-
tages and feasibility of integrating transcriptomics with genomics
to reveal pathogenic noncoding mutations in unsolved human
Mendelian diseases.
Results
Clinical features of microcephaly-micromelia syndrome
MMS (MIM 251230) is characterized by IUGR, marked microceph-
aly with distinctive craniofacial features, limbmalformations, and
nearly uniform perinatal lethality due to respiratory failure. The
growth restriction and microcephaly are severe, with term (≥38-
wk gestation) birth weights between 0.8–1.6 kg (average 1.2 kg;
average z-score −6.5; n = 15), average head circumferences of 24
cm (z-score −7.4; n = 7), and average lengths of 34 cm (z-score
−7.4; n = 12). Affected individuals have a characteristic facial ap-
pearance with a broad and beaked nose, short palpebral fissures,
microstomia, micrognathia, low-set ears, and a short neck (Fig.
1A). Both upper and lower limbs are malformed, with upper limbs
more severely affected—forearms are short, with frequent absence
or significant underdevelopment of the radius and/or ulna and
often humeroradial synostosis (Fig. 1A). Nearly all individuals
have bilateral oligodactyly with absent thumbs, and most have
absent or poorly developed fifth fingers that sometimes arise
from a bifid metacarpal bone (Fig. 1B). Lower limbs are sometimes
shortened with an underdeveloped fibula, feet are often clubbed
with variable toe syndactyly, the great toes can be short and/or
proximally placed, and in some cases, the fourth and fifth
metatarsal bones and toes are underdeveloped or absent (Fig.
1B). Additionally, many affected individuals have complete
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craniosynostosis and other skeletal
anomalies such as absence of one or
two pairs of ribs.
BrainMRIs of individuals withMMS
show several characteristic anomalies,
including profound microcephaly with
only primary sulci and gyri, diminished
whitematter, a hypoplastic or absent cor-
pus callosum, aqueductal stenosis, and a
large interhemispheric cyst; other gross
brain structures are present, and the cere-
bellum is relatively preserved (Fig. 1C).
Histological analysis of the cerebral cor-
tex shows a simplified gyral pattern, re-
duced white matter, decreased cells in
the subventricular zone, and a disorga-
nized distribution of cells with clusters
of neurons and vertically oriented col-
umns of neurons separated by cell-sparse
zones (Fig. 1D).
The lungs of individuals with MMS
are severely hypoplastic with anomalous
lobation. As a result, nearly all cases iden-
tified to date were either stillborn or died
within the first week of life due to respira-
tory failure; the only known exceptions
are two affected children who died at 3
mo and 2 yr of age from respiratory com-
plications. Additionally, cleft palate and
cardiac, gastrointestinal, and genitouri-
nary defects are observed in some cases.
While IUGR, microcephaly, and dwarf-
ism are also seen in MPD syndromes
(Klingseisen and Jackson 2011), the com-
bination of the characteristic craniofacial
anomalies, limb malformations, and
neonatal lethality is distinct and diag-
nostic for MMS.
Microcephaly-micromelia syndrome is
linked to a locus on Chromosome 21q
Most individuals with MMS in this study
belong to a large and consanguineous
pedigree of First Nations origin in
Saskatchewan, showing autosomal re-
cessive inheritance (Fig. 1E). Other cases
belong to the same population and are
known to be descendants of the founders
of this pedigree, though their exact rela-
tionships are unknown (Fig. 1E; see Sup-
plemental Data 1 for a list of all profiled
individuals). High-density genome-wide
single nucleotide polymorphism (SNP)-
microarray genotyping of seven affected
individuals and 15 unaffected parents
followed by linkage analysis under a re-
cessive inheritance model identified an
852-kb (1.2 cM) locus on Chromosome
21q22.11 definitively associated with
the disease with a maximum combined
logarithm of odds (LOD) score of 9.2
Figure 1. Microcephaly-micromelia syndromephenotype and pedigrees. (A) Photographs of an affect-
ed individual (12601) illustrating the severe microcephaly, facial dysmorphisms, and limb anomalies
characteristic of microcephaly-micromelia syndrome. (B) Photograph of a foot (individual 15204) and
photograph and X-ray of a hand (individual 12601) showing both pre-axial (malformed toe and absent
thumb) and post-axial (underdeveloped fifth metatarsal bone, and hypoplastic fifth digit arising from
bifid fourthmetacarpal bone) abnormalities. (C ) BrainMRIs of two affected individuals showing the com-
mon structural brain abnormalities of MMS: profound microcephaly, simplified gyral pattern, markedly
diminished white matter volume and myelination, hypoplastic or absent corpus callosum, aqueductal
stenosis, and a small pons. Note the large dorsal interhemispheric cysts in both individuals, which was
present in nearly every affected individual examined byMRI or autopsy to date. Cortical thickness is gross-
ly normal and the cerebellar hemispheres are relatively large compared to the rest of the brain. Head cir-
cumferences (HC) and z-scores (number of standard deviations [SD] from the mean of newborns of the
same gestational age at birth) are shown. MRI sequences were as follows: 12601: axial T2 (top left), mid-
sagittal T1 (top right), left-sagittal T1 (bottom right), coronal T2-FIESTA (bottom left); 15204: axial T2 (top),
coronal T2-HASTE (bottom). White scale bars = 1 cm. (D) Brain histology of MMS cases. (Left) Low-power
Nissl-stained brain section of a child who died at 3 mo of age showing simplified gyral pattern and re-
duced white matter (CG) cingulate gyrus, (CC) corpus callosum, (LV) lateral ventricle, (Cd) caudate,
(P) putamen, (GP) globus pallidus, (OT) optic tract). (Top right) Cresyl violet-stained brain section of a
35-wk-gestation newborn at the angle of the lateral ventricle (LV) showing decreased cells in the subven-
tricular zone (SVZ; arrow). Bar = 100 μm. (Middle right) Hematoxylin- and eosin-stained section of the ce-
rebral cortex of a 41-wk-gestation newborn demonstrating disorganized clusters of neurons (arrows)
separated by cell-free zones in superficial layers. Bar = 100 μm. (Bottom right) Cresyl violet-stained section
from a full-term newborn cerebral cortex demonstrating the persistence of radial columns of neurons
separated by cell-sparse regions. Bar = 500 μm. (E) Pedigrees of the families with MMS profiled in this
study. Individual IDs are labeled for individuals whose samples were profiled. The pedigree at the top
left can be linked via individuals VII:7 and VIII:2 to the larger pedigree in the original description of the
syndrome by Ives and Houston (Ives and Houston 1980). Gray symbol (top right pedigree) represents
a child that died in infancy with limb anomalies, but the specific diagnosis of MMS was not confirmed.
Deceased status is indicatedwith crossed-out symbols for affected individuals only and not for unaffected
individuals. For simplicity, not all individuals of the pedigrees are illustrated. See Supplemental Data 1 for
a list of all case samples in this study.
Mutation of genome replication factor DONSON
Genome Research 3
www.genome.org
 Cold Spring Harbor Laboratory Press on July 27, 2017 - Published by genome.cshlp.orgDownloaded from 
(Fig. 2A). Homozygosity and haplotype analysis using SNP-micro-
array genotypes of affected cases further narrowed this region to a
664-kb minimal overlapping region of homozygosity (ROH)
(rs9978569 to rs4443074; Chr 21: 33,364,965–34,029,433;
GRCh38/hg38) (Fig. 2B).
Multimodal genome sequencing of the disease
locus fails to identify plausible exonic or canonical
splice mutations
We sequenced three affected individuals using three different
methods: whole-exome sequencing (WES, individuals 412 and
13001), targeted-capture sequencing of the linkage region (indi-
vidual 13001), and whole-genome sequencing (WGS, individual
12601). Thesemethods covered 97.0%, 99.8%, and 97.9%, respec-
tively, of the coding exome in the ROH with ≥10× read depth (see
Supplemental Fig. 1A for coverage statistics). Targeted-capture and
WGS covered 83% and 98% of the entire ROH (i.e., coding exons,
introns, UTRs, and intergenic regions), respectively, with ≥10×
read depth (Supplemental Fig. 1A). The variants identified by the
three methods were highly concordant, though some variants
were identified by only one or two of the three methods
(Supplemental Fig. 1C,D; Supplemental Data 2). After filtering
out common population variants, no rare coding (either synony-
mous or nonsynonymous) or canonical splice site mutations
(i.e., within 2 bp of the intron-exon junction)were identifiedwith-
in the ROH by any of these sequencing approaches (Table 1;
Supplemental Fig. 1B). In contrast, 18 rare intronic and 20 rare
intergenic noncoding variants were identified in the ROH (Table
1; Supplemental Fig. 1B; Supplemental Data 2). Analysis of highly
Figure 2. Linkage and homozygosity analysis identifies a locus on Chromosome 21q22.11. (A) Linkage analysis using SNP-microarray genotypes of af-
fected individuals and unaffected parents (see Supplemental Data 1 for list of genotyped individuals) identified a locus associated with the disease at
Chromosome 21q22.11 with maximum LOD score of 9.2 (purple star; interval: Chr 21: 33,344,469–34,196,070; GRCh38/hg38). (B) SNP-microarray ge-
notypes in the interval defined by linkage analysis (Fig. 2A). Each line represents an individual (unaffected parents on top and affected individuals labeled in
bold on bottom). Each column in the SNP ideogram represents a SNP, with homozygous alleles in red or blue and heterozygous alleles in green. Affected
individuals 421 and 12601 define aminimal region of overlapping homozygosity (ROH) at 21q22.11 (blue box and line; Chr 21: 33,364,965–34,029,433;
GRCh38/hg38). RefSeq gene annotations are shown above. Low quality SNP calls are omitted. Note: samples 418 and 419 are shown here but these were
not used for linkage analysis since they did not pass quality control filters (see Supplemental Methods).
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conserved noncoding elements in the region did not aid in further
narrowing the list of noncoding variants.
Furthermore, copy number variant (CNV) and structural
variant analyses were performed using the targeted-capture and
WGS data. CNV analysis was also performed by a targeted array
comparative genomic hybridization experiment. None of these
methods identified a CNV or structural variant in the ROH
(Table 1; Supplemental Fig. 1B).
RNA-seq identifies a splicing defect associated with an intronic
variant in DONSON
Since comprehensive genome-sequencing did not reveal a coding
or canonical splicingmutation in theMMS ROH, we hypothesized
that one of the 38 noncoding variants detected in the ROH may
be the cause of the disease and that transcriptome profiling of
affected samples could reveal which of these noncoding muta-
tions causes MMS via cis effects on gene expression or splicing.
We therefore performed RNA-seq of wild-type control (n = 13),
heterozygous parent (n = 6), and homozygous MMS case samples
(n = 11) derived from a variety of cell lines and tissues.
RNA-seq analyses of gene expression and splicing in the 30
samples from affected and unaffected individuals identified only
one abnormality within the ROH in MMS samples: significantly
increased retention of intron 6 of DONSON in MMS samples
relative to heterozygous parent and wild-type control samples
(Fig. 3A). Importantly, intron 6 of DONSON contained one of
the 38 noncoding variants identified previously by genome
sequencing, an A to G transition (in the transcript sense
strand) located 9 bp upstream of the intron 6–exon 7 junction
(DONSON [NM_017613.3]:c.1047-9A>G; Chr 21[NC_000021.8]:
g.33582064T>C [GRCh38;hg38]) (Supplemental Data 2). The
only two other variants inDONSONwere located distantly in other
introns, 1.2 kb (intron 5) and 2.4 kb (intron 4) away (Supplemental
Data 2). Furthermore, MMS samples showed no evidence of any
novel DONSON isoforms, such as might arise from activation
of cryptic 5′ splice donor or 3′ splice acceptor sites within intron
6. Retention of intron 6 creates a premature stop codon after 52
bp of the 109-bp intron, which is predicted to lead to nonsense-
mediated decay (NMD) of the mutant transcript (Wong et al.
2016) or to a truncated protein (366 amino acids versus wild-
type 566 amino acids) that ends with 17 aberrant amino acids
due to translation of the first half of intron 6 (Fig. 3D). Overall,
DONSON expression levels in RNA-seq showed a trend toward low-
er expression in heterozygous parents and homozygous MMS cas-
es, but these differences were not statistically significant (controls:
5.2 ± 2.8 fragments per kilobase per million mapped reads [FPKM
mean ± std dev], parents: 3.9 ± 2.4 FPKM, MMS cases: 3.4 ± 1.7
FPKM; P-value >0.05 for all comparisons). However, a more sen-
sitive TaqMan qPCR assay confirmed significantly decreased
DONSON transcript levels in the presence of the MMS variant
(56% of wild-type levels in heterozygous cell lines; 95% con-
fidence interval: 44%–72%) (Supplemental Fig. 2C), consistent
with NMD of the mutant transcript. Altogether, these results sug-
gest that MMS is caused by the c.1047-9A>G noncoding variant
in DONSON via an intron retention mechanism.
Genotyping of the intron 6 noncoding variant across all
available samples from the extended MMS pedigrees confirmed
it was homozygous in all affected individuals and heterozygous
in all parents (Supplemental Data 1). The variant was absent
from the NHLBI Exome Sequencing Project (6503 individuals),
the 1000Genomes Project, a set of 69 Complete Genomics control
genomes, and 1464 unrelated exomes previously sequenced byour
laboratory. The variant was found in the heterozygous state in one
of 736 additional neurologically normal control samples that we
genotyped and in six of 121,390 chromosomes in the Exome
Aggregation Consoritum (ExAC) database, all in the heterozygous
state in European individuals (Supplemental Data 2). The locus
of this intronic variant is captured well by exome sequencing
due to its relative proximity to an intron-exon junction (e.g., the
locus was called in 121,390 of 121,412 chromosomes in ExAC),
so its low frequency in control exomes was not due to inefficient
capture. The extremely low allele frequency of the variant across
these studies (5 × 10−5), along with the unique hypomorphic
nature of the allele and the essential requirement for DONSON
in body development (see below analyses), is consistent with the
extreme rarity of the microcephaly-micromelia syndrome.
In order to independently confirm and quantify the splice
defect identified by RNA-seq, we designed a reverse transcriptase-
polymerase chain reaction (RT-PCR) assay for intron 6 retention
using primers flanking intron 6, from exon 6 to exon 7. The assay
confirmed the intron 6 retention defect in all MMS samples
and showed a mild but detectable increase in intron retention
in heterozygous parents relative to control samples (Fig. 3E;
Supplemental Fig. 2A). Interestingly, the assay also showed that
splicing of intron 6 is not perfectly efficient in control sam-
ples, with low and variable levels of intron 6 retention in normal
tissues, though significantly less than in the MMS samples (Fig.
3E; Supplemental Fig. 2A). The RT-PCR assay employed a fluores-
cent primer (Fig. 3E schematic), allowing quantification of the
Table 1. Variants identified in the MMS region of homozygosity by genomic DNA sequencing
Individual
Sequencing
method
Coding
exon
Splice
site
Noncoding
RNA exon UTR Intron
±1 kb of
transcript
start/stop
Other
intergenic SV
Total
coding or
splice site
Total
noncoding
412 Whole-exome seq 0 0 0 0 3 0 0 N/A 0 3
13001 Whole-exome seq 0 0 0 0 2 0 1 N/A 0 3
13001 Targeted-capture seq 0 0 0 0 14 1 18 0 0 32
12601 Whole-genome seq 0 0 0 0 12 0 6 0 0 18
Detected by at least 1 method: 0 38
Number of homozygous single-nucleotide variants identified in the microcephaly-micromelia syndrome minimal region of homozygosity (ROH), cate-
gorized by variant type, after filtering out variants found at ≥1% allele frequency in public variant databases (see Methods). Coding exon variants
include nonsense, missense, frameshift, and synonymous variants. Splice site variants are intronic variants within 2 bp of the intron-exon junction. UTR:
untranslated regions; ±1 kb of transcript start/stop: variants within 1 kb of transcript start or stop sites. SV: Structural variants. See Supplemental Figure
1 for number of variants prior to population variant filtering and for concordance of detection between the sequencing methods. See Supplemental
Data 2 for a full listing of the variants identified.
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Figure 3. RNA-seq identifies an intron-retention splicing defect associated with an intronic variant in DONSON. (A) RNA-seq read coverage for represen-
tative samples shows aberrant retention of intron 6 of DONSON (red bar) in affected individuals associated with the c.1047-9A>G noncoding mutation
(Chr 21: g.33582064:T>C; red asterisk). The interval shown is Chr 21: 33,580,994–33,583,594 (GRCh38/hg38), illustrated in the reverse strand direction.
The genotype of each sample is shown on the right. HomozygousMMS, heterozygous parent, and wild-type control sample names are colored red, purple,
and black, respectively. Read coverage graph Y-axes are scaled (numbers on right side of Y-axis) to show the maximum coverage of each sample in the
interval. (B) RNA-seq quantification of intron retention for each intron of DONSON, based upon pooling all the RNA-seq samples of each genotype
(see Supplemental Methods for details). Cells are shaded green to red according to the percentile between theminimum andmaximum values in the table.
The aberrant retention of intron 6 is highlighted. The table also shows the mild increase in intron 6 retention in heterozygous parents relative to wild-type
controls and the baseline low-level retention of intron 6 in controls relative to other introns. MMS individuals also showed a trend of increased retention
of other introns upstream of intron 6, suggesting that impaired splicing of intron 6might affect splicing of other introns; however, themechanism bywhich
this would occur is unclear. (C ) RNA-seq quantification of intron 6 retention calculated as in Figure 3B. Error bars are 95% confidence intervals
(see Supplemental Methods). All group comparisons were significant: controls versus parents: P = 0.03; controls versus affected: P < 10−15; parents versus
affected: P < 10−15 (Fisher’s exact test with Holm multiple comparisons adjustment). (D) Schematic of the intron retention splicing defect caused by the
c.1047-9A>G (Chr 21: 33582064 T>C) mutation in intron 6 in microcephaly-micromelia syndrome. Retention of intron 6 would lead to either nonsense-
mediated decay of the transcript due to the stop codon within intron 6 or to a truncated protein. On the right are the predicted wild-type and truncated
mutant proteins and their amino acid (AA) lengths. Translation of the first part of the aberrantly retained intron 6 creates 17 amino acids followed by a
premature stop codon. (E) RT-PCR spanning from exon 6 to exon 7 of DONSON (top schematic) in various tissues confirms increased retention of intron
6 inMMS samples, which are homozygous for the Chr 21: 33582064 T>Cmutation, compared to heterozygous parents and wild-type controls (unspliced
transcript with intron 6: 230 bp; spliced transcript: 121 bp). Shown here are six representative samples for each genotype. (Note that the variant is A>G in
the DONSON transcript strand and T>C in the genomic plus strand). See Supplemental Figure 2A for RT-PCR gel images of all assayed samples. The exon 7
PCR primer contains a FAM fluorescent label (green circle) for quantification of PCR products (Fig. 3E). Wild-type (T/T) samples: 1- FU-009 umbilical
cord; 2- FU-006 umbilical cord; 3- FU-004 umbilical cord; 4- fetal liver; 5- fetal brain; 6- cerebellum. Heterozygous (T/C) parent samples: 1- 15603 cell
line; 2- 15602 cell line; 3- 15202 cell line; 4- 15201 cell line; 5- 15202 blood sample a; 6- 15202 blood sample b. Homozygous (C/C) MMS samples:
1- 15204 brain (RNAlater); 2- 15204 brain (fresh-frozen sample a); 3- 15204 brain (fresh-frozen sample b); 4- 15204 heart (RNAlater); 5- 15204 heart
(fresh-frozen); 6- 15204 kidney (RNAlater). (F) Quantification of the RT-PCR intron 6 retention assay products. RT-PCR was performed with the PCR primer
for exon 7 containing a FAM-fluorescent label allowing quantification of the RT-PCR products with a capillary electrophoresis DNA analyzer (see Methods).
Percentage unspliced RT-PCR product was calculated as [Area of unspliced band]/[Area of unspliced band + Area of spliced band], and averaged across all
samples of each genotype (number of samples in each group is shown on top). Groups were significantly different from each other (Controls versus Parents,
P = 0.005; Controls vs. Affected, P < 10−22; Parents vs. Affected, P < 10−7; two-tailed unpaired t-test). Importantly, note that this measurement can be used
to evaluate relative splicing differences between genotypes but is not an absolute measurement of splicing, since the PCR amplification efficiencies of the
unspliced and spliced products differ. See Supplemental Figure 2A for percentage unspliced RT-PCR product of all assayed samples and Supplemental
Figure 2B for percentage unspliced RT-PCR product summarized by tissue type for brain, umbilical cord, and cell lines/blood leukocytes.
6 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on July 27, 2017 - Published by genome.cshlp.orgDownloaded from 
two RT-PCR products (spliced product and intron 6 retention pro-
duct). The intron 6 retention amplicon was, on average, 85 ± 5%
(standard deviation) of the total RT-PCR product in homozygous
MMS samples, 38 ± 13% in heterozygous parent samples, and 24
± 10% in wild-type control samples (Fig. 3F). All differences in
intron 6 splicing between the groups of samples were statistically
significant (controls vs. parents, P = 0.005; controls vs. affected,
P < 10−20; parents vs. affected, P < 10−5; two-tailed unpaired t-test
with Holm multiple comparisons adjustment) (Fig. 3F). These
RT-PCR results confirm a significant intron 6 retention splice
defect ofDONSON inMMS samples, a small but detectable increase
in intron 6 retention in heterozygous parents, and that intron 6
splicing is not perfectly efficient in normal tissues.
The above RT-PCR assay allows robust comparisons of the rel-
ative efficiency of intron 6 splicing between samples; however,
because the RT-PCR amplification efficiency of the spliced and
unspliced products may differ due to their different sizes, the assay
might not be a fully accurate measure of absolute splicing efficien-
cy. We therefore also estimated intron 6 retention using the RNA-
seq data by counting the number of intron–exon junction span-
ning reads (reflecting intron retention) versus exon 6–exon 7 splice
reads (reflecting intron splicing). In MMS samples, 66% of these
reads at the intron 6 locus were intron–exon junction spanning
reads that arose from DONSON transcripts retaining intron 6, ver-
sus 12% in heterozygous parents and 7% in controls (Fig. 3A–C).
The differences between each category of samples were statistically
significant (controls versus parents: P = 0.03; controls versus
affected: P < 10−15; parents versus affected: P < 10−15; Fisher’s exact
test with Holm multiple comparisons adjustment). Furthermore,
in heterozygous parent samples, more intron 6-retaining tran-
scripts were derived from the mutant allele than the wild-type
allele: 69% of RNA-seq reads at the intron 6 mutation locus
(pooled from all heterozygous samples) contained the mutation
(P = 0.02; binomial test versus the expected 50% if there were no
association between the intron retention and the mutant allele).
The above RNA-seq results again confirm that (1) individuals
with MMS have a hypomorphic DONSON allele in which most
transcripts retain intron 6, while a small fraction of transcripts
are correctly spliced, (2) there is a small increase in intron 6 reten-
tion in heterozygous parents relative to controls, (3) the intron 6
variant is associated in cis with intron 6 retention, and (4) there
is baseline low-level retention of intron 6 in wild-type tissues.
Notably, plotting of intron retention estimated by RNA-seq
across all introns of DONSON and all sample types showed not
only the specific intron 6 retention defect, but also that in wild-
type control tissues, intron 6 is one of the gene’s least efficiently
spliced introns (Fig. 3B). Therefore, the low level of intron 6 reten-
tion seen in control samples by RNA-seq and RT-PCR is not due to
overall splicing inefficiency in the assayed samples or global cap-
ture of unspliced transcripts during RNA-seq sample preparation,
but rather a specific feature of intron 6. The baseline decreased
efficiency of intron 6 splicing compared to other intronsmight ex-
plain the intron’s susceptibility to the MMS c.1047-9A>G intronic
mutation.
DONSON is essential for early embryonic development and is
associated with components of the DNA replication machinery
In order to determinehow theMMSphenotype relates toDONSON
function during development, we assessed DONSON expression
inhumanandmouse embryos by in situ hybridization. In bothhu-
man and mouse, we found that DONSON is expressed in multiple
organsof thedeveloping embryo, including thebrain, heart, lungs,
gastrointestinal tract, limbs, and kidneys (Supplemental Figs. 3A–
C), which grossly corresponds to the organs affected in MMS.
Because MMS has a severe microcephaly phenotype, we
assessed DONSON expression in greater detail in human and
mouse embryonic and fetal brains. These in situ hybridization
studies found that DONSON is highly enriched in the ventricular
and subventricular zones of the neocortex, which contain prolifer-
ating progenitor cells, as well as in the cortical plate containing
newborn neurons, and the ganglionic eminences (Fig. 4A–D).
This pattern of expression is consistent with the observed simpli-
fied gyral pattern, reduced white matter, and disorganized cortical
columns seen in histology of MMS brains (Fig. 1D). We also inves-
tigated DONSON expression in a prior transcriptomic study of
laser-microdissected regions of the developing human brain
(Miller et al. 2014) and found a similar pattern of expression:
in 15- and 16-wk-post-conception (wpc) human fetal brains,
DONSON is highly expressed in the ventricular and subventricular
zones, respectively; it is highly expressed in the ganglionic
eminence of 15-wpc brain and subplate of 16-wpc brain, and in
21-wpc neocortex, DONSON expression is highest in the cortical
plate (Supplemental Fig. 4A). Loss of DONSON function in early
neocortical progenitor cells is consistent with the profoundmicro-
cephaly and brain malformations of MMS. Furthermore, assays of
DONSON expression across a broad range of prenatal and adult
time points as part of the Human Brain Transcriptome project
(Kang et al. 2011) show that DONSON expression is higher in
prenatal brain relative to adult brain across all profiled brain re-
gions (Supplemental Fig. 4B), supporting an important role for
DONSON specifically during brain development.
To confirm the essential role ofDONSON inprenatal develop-
ment, we also analyzed the phenotype of Donson knockout mice,
which were created as part of the International Knockout Mouse
Consortium. Matings between mice heterozygous for a Donson
loss-of-function allele did not yield any homozygous pups, and
genotyping of E9.5, E12.5, and E14.5 embryos did not detect any
homozygous embryos (Table 2), indicating that complete loss of
DONSON function is lethal during early murine embryonic devel-
opment. Heterozygous knockout mice were phenotyped on >150
anatomic and laboratory measures (including brain weight) via
the standardized International Mouse Phenotyping Consortium
protocol (Supplemental Methods; White et al. 2013), with no ma-
jor discernible abnormalities detected, though it is possible that
subtle brain phenotypes could be revealed by additional detailed
neuroanatomic studies. The essential role of DONSON in organis-
mal development is also supported by phylogenetic analyses—
DONSON is conserved across all multicellular eukaryotes, with
orthologs found inmammals, birds, reptiles, insects, roundworms,
plants, and fungi (Supplemental Fig. 5B; Bandura et al. 2005).
We utilized public proteomic and gene expression databases
to identify complexes and proteins with which DONSON may
function in the cell cycle. The Drosophila Protein Interaction
Map project, which used tagged proteins to profile the Drosophila
proteome, found that Humpty Dumpty, DONSON’s ortholog
in fly, is the highest-ranked interactor of Asf1 (Guruharsha et al.
2011; Chatr-Aryamontri et al. 2015). Asf1 is a histone chaperone
that coordinates nucleosome assembly on newly replicated
DNA with chromatin unwinding by the MCM2-7 prereplicative
and replication helicase complexes. This points to a role for
DONSON in the genome replication machinery.
Next, we mined the COXPRESdb database (Okamura et al.
2015), which collates thousands of microarray and RNA-seq
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samples from various species to create robust lists of co-expressed
genes, and found further independent validation of an association
between DONSON and components of the DNA replication and
replication fork machinery. In Drosophila, more than half of the
top 20 genes most highly co-expressed with humpty dumpty have
known roles in the DNA replication complexes, including (1)
DNA polymerase subunits involved in initiation of replication:
DNApol-alpha73 [POLA2] andDNApol-al-
pha60 [PRIM2] (human homologs in
brackets), (2) DNA polymerase processiv-
ity factors: RfC38 [RFC3], CG8142
[RFC4], and CG11788 [DSCC1] that
help load the PCNA sliding clamp,which
mediates polymerase processivity, onto
primed DNA (Bermudez et al. 2003;
Bowman et al. 2004), (3) DNA ligase 1
(DNA-ligI [LIG1]), which joins Okazaki
fragments during DNA replication and
is also associated with PCNA, (4) com-
ponents of the DNA replication pre-ini-
tiation and replication fork complexes:
CG3430 [MCMBP], Mcm3 [MCM3],
Cdc45 [CDC45], (5) Orc2 [ORC2], a com-
ponent of the origin recognition com-
plex, and (6) regulators of the cell cycle:
Lethal-(2)-denticleless [DTL]—which codes
for a ubiquitin ligase targeting key cell cy-
cle regulators and associated with PCNA
and the DNA replication licensing factor
CDT1 (Higa et al. 2006), and Cortex—a
member of the Cdc20/fizzy family of cell
cycle regulators (Nadeau et al. 2016).
In the humanCOXPRESdb data, the
top genes most highly co-expressed with
DONSON were again strikingly enriched
for genes coding for components of the
DNA replication machinery, including
(1) the ORC1 origin recognition complex
subunit 1, (2) CDC6, which together
with CDT1 loads the MCM2-7 replica-
tion helicase onto replication origins,
(3) GINS1, a component of the active
CMG (CDC45/MCM2-7/GINS) replica-
tion helicase, (4) MCM4 and MCM6,
components of the MCM2-7 helicase,
(5) POLE2, a subunit of DNA polymera-
se-epsilon, (6)MCM10, an essential com-
ponent of the replication fork that
mediates the association of MCM2-7
and DNA polymerase-alpha with repli-
cation origins (Homesley et al. 2000;
Ricke and Bielinsky 2004), (7) CHAF1B,
a subunit of the chromatin assembly
factor that loads histones onto newly
replicated DNA (Volk and Crispino
2015), and (8) cell cycle regulators:
CDK1, DTL, cyclin E2, and cyclin A2 (a
regulator of origin of replication firing).
A similarly remarkable enrichment
of replication complex genes was seen
in mouse and rat COXPRESdb data, in-
cluding Orc6, Cdt1, Cdc6, Mcm2, Mcm3,
Mcm4, Pcna, Dscc1, Fen1 (the endonuclease processing Okazaki
fragments), and cyclin E1—all of which were within at least one
of the two species’ top 20 genes most highly co-expressed with
Donson.
Finally, to confirm an effect ofDONSON loss on cell cycle pro-
gression, we assayed the expression of a panel of cell cycle genes
(i.e., cyclins, cyclin-dependent kinases, checkpoint regulators) by
Figure 4. DONSON expression in human and mouse brain development. (A) DONSON expression by
in situ hybridization in a coronal section of a 9-wk-gestation human fetal brain. Expression is prominent in
the neocortex subventricular zone, which contains progenitor cells, and in the cortical plate, where newly
born neurons reside. Expression is also seen in the ganglionic eminences, which give rise to the basal gan-
glia and interneurons thatmigrate into the neocortex. Scale bar formain image (left) is 500 µm; scale bars
for other images are 100 µm. Hybridization was performed with antisense probe 1 (see Supplemental
Methods). (Ctx) Neocortex, (GE) ganglionic eminence, (v) ventricular zone, (sv) subventricular zone,
(i) intermediate zone, (c) cortical plate, (m) marginal zone. (B) DONSON expression by in situ hybridiza-
tion in a sagittal section of a 12-wk-gestation human fetal brain. Expression is prominent in the basal gan-
glia (BG) and the ventricular and subventricular zones and cortical plate of the neocortex (Ctx),
mesencephalon (M, midbrain), and rhombencephalon (R, hindbrain). Scale bar for main image (left)
is 1000 µm; scale bars for other images are 100 µm. Hybridization was performed with antisense probe
1. (C) DONSON expression by in situ hybridization in a coronal section of a hemisphere of a 20-wk-ges-
tation human fetal brain. Expression is evident in the ventricular and subventricular zones, intermediate
zone, and cortical plate of the neocortex (Ctx). Scale bar for main image (left) is 1000 µm; scale bar for
other image is 100 µm. Hybridization was performedwith antisense probe 2. (D)DONSON expression by
in situ hybridization in a coronal section of an E15.5 mouse brain. Expression is evident in the ventricular
(v) and subventricular zones (sv), intermediate zone (i), and cortical plate (c) of the neocortex. Scale bar
for top and bottom images are 500 and 100 µm, respectively. Hybridization was performed with human
antisense probe 3. For all above tissue sections, negligible signal was observed with sense sequence
probes in adjacent sections (Supplemental Fig. 3D), confirming specificity of the antisense probe
staining.
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qPCR after siRNA knockdown of DONSON in HeLa cells. After
DONSON knockdown, the most significantly up-regulated gene
in the panel was CDKN1A (p21), and the most significantly
down-regulated genes were cyclin D2 and cyclin E2
(Supplemental Fig. 4C). Since p21 inhibits, and cyclins D2 and
E2 mediate, the G1/S phase transition (Vermeulen et al. 2003),
these results are consistent with arrest prior to or slowed progres-
sion through S phase seen withDONSON loss in fly and HeLa cells
in prior studies (Bandura et al. 2005; Fuchs et al. 2010). It also sug-
gests that p21 up-regulationmediates the cell cycle arrest triggered
by DONSON loss. Further evidence that DONSON loss impairs cell
proliferation is that, despite multiple attempts, we have been un-
able to culture cell lines from affected MMS patients—the cells
die after their derivation and cannot be expanded in vitro, while
multiple cell lines from their unaffected parents grow normally.
Altogether, the above data strongly suggest that DONSON
is essential for genome replication, and therefore cell proliferation
and early embryonic development, via a regulative or integral
function in the prereplication and/or replication fork complexes,
which notably, are disrupted in other MPD syndromes.
Discussion
Here, we present a noncoding mutation in DONSON as the cause
of microcephaly-micromelia syndrome and link DONSON to
the key complexes mediating genome replication that are dis-
rupted in other microcephalic primordial dwarfism syndromes.
Identification of this unusual hypomorphic mutation—in an
essential gene whose complete loss of function we predict would
otherwise be embryonic-lethal—was facilitated by a genomic
plus transcriptomic integrated approach that serves as a model
for discovering causes of other Mendelian diseases for which ge-
nome sequencing alone has been unsuccessful.
A transcriptomic approach facilitates the discovery of variants
causing Mendelian disease
Our study illustrates how transcriptome sequencing (RNA-seq) can
provide in vivo functional evidence for rapid identification of
pathogenic variants, in particular those that alter gene expression
or splicing. While our study identified an unexpected noncoding
mutation in a novel disease gene, several prior studies have also
shown the potential of RNA-seq for discovering splicing perturba-
tions in known human disease genes (Chandrasekharappa et al.
2013), splicing defects caused by variants in canonical (i.e., pre-
dictable) splice sites of genes not previously associatedwith disease
(Wang et al. 2013), fusion transcripts in cancer (Pierron et al. 2012;
Morin et al. 2013), and RNA-seq confirmation of known transcrip-
tion-altering mutations from genetic screens in model organisms
(Miller et al. 2013). These studies also identified decreased tran-
script levels due to nonsense-mediated decay and other unexpect-
ed splice defects such as missense and synonymous exonic
mutations causing exon skipping (Chandrasekharappa et al.
2013; Miller et al. 2013). We have also previously used RNA-
seq to confirm a splicing defect that we had first identified by tra-
ditional molecular biology methods in the ZNF335 gene causing
microcephaly (Yang et al. 2012). RNA-seq showed that the patho-
genicmissensemutation in the last base of one of the gene’s exons
caused retentionnot just of the immediately following intron, but,
unexpectedly, also the preceding intron. These examples empha-
size the complex and unpredictable nature of splicing mutations
and the utility of RNA-seq as a high-throughput adjunct assay to
DNA sequencing in assessing the transcriptional impact of both
coding and noncoding variants.
RNA-seq has several additional important advantages. First,
RNA-seqmight allow direct identification of the pathogenicmuta-
tion and transcriptional defect without prior variant filtering or
linkage analysis. While in our study of DONSON, the retained in-
tron 6 is short and cannot provide such genome-wide power of
detection, in some cases, RNA-seq of a single proband could be suf-
ficient for identifying the disease-causing variant. For example, in
our earlier study of ZNF335, the retained long intron ranked as the
fourth most significant differentially transcribed intron out of
>350,000 RefSeq-annotated introns, and the other top entries
were false-positives due to unannotated exons (Yang et al. 2012).
Situations that could feasibly provide such power for genome-
wide detectionwould be the retentionof long introns and aberrant
splice donor or acceptor sites, which provide greater signal to back-
ground ratios than other defects such as exon-skipping that are
more common normal alternative splice events.
Second, RNA-seq can reveal allelic association of variants to
abnormal transcripts, providing additional functional evidence
of causality. In heterozygous samples, biased expression of an ab-
errant transcript from the variant allele, as seen with theDONSON
mutation, indicates that the variant causes the abnormal tran-
script in cis. Third, RNA-seq provides a functional read-out of the
entire in vivo context of variants, which is not fully recapitulated
in minigene and other reporter assays.
On the other hand, RNA-seq is limited by its dependence on
whether the affected gene is normally expressed in the available
Table 2. Donson loss of function is lethal in early embryonic mouse development
Age Total pups Wild type Heterozygotes Homozygotes Resorption count
E9.5 30 11 (37%) 19 (63%) 0 (0%) 20
E12.5 18 5 (28%) 13 (72%) 0 (0%) 12
E14.5 40 14 (35%) 26 (65%) 0 (0%) 6
P14 52 17 (33%) 35 (67%) 0 (0%) N/A
Number of mouse pups at embryonic days (E) 9.5, 12.5, and 14.5, and postnatal day (P) 14, that were wild type, heterozygous, or homozygous for a
Donson gene-trap knockout cassette (Donsontm1a(EUCOMM)Wtsi) in a cross of two heterozygous Donsontm1a(EUCOMM)Wtsi/+ mice. Two embryos in each of
E9.5 and E12.5 stages failed genotyping and were excluded. In parentheses are the percentages out of the total number of wild-type, heterozygous,
and homozygous pups. The genotypes found at each age were significantly different than the expected 1:2:1 ratio of wild-type:heterozygote:homozy-
gote genotypes (P = 0.006, P = 0.042, P = 0.001, P = 2 × 10−4, for E9.5, E12.5, E14.5, P14, respectively; χ2 test). The genotypes were not significantly
different from a 1:2 ratio of wild-type:heterozygote genotypes that would be expected from complete lethality of homozygous embryos (P = 0.70, P =
0.62, P = 0.82, P = 0.92, for E9.5, E12.5, E14.5, P14, respectively; χ2 test). Resorption events are embryos that implanted but were reabsorbed before
dissection, with only the maternal decidua remaining such that the embryo’s genotype cannot be determined. A proportional greater number of re-
sorption events were found at earlier stages, which are presumably remnants of homozygous pups.
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tissues at sufficient levels to allow detection of abnormal tran-
scripts. The feasibility of a transcriptomic approach therefore de-
pends on the studied disease and the accessibility of affected
tissues. One possible approach when affected tissues are not avail-
able may be to create induced pluripotent stem cells from patient
samples and to differentiate them into the cell types affected
by the disease, thereby allowing RNA-seq analysis of the disease-
relevant mRNA species.
Intron retention as a mechanism of genetic disease
While progress has been made in understanding the mechanisms
of RNA splicing and how splicing patterns relate to DNA se-
quence (Barash et al. 2010; Xiong et al. 2015), much of the geno-
mic code mediating splicing remains unknown (Lewandowska
2013; Guigo and Valcarcel 2015; Lee and Rio 2015). Intron reten-
tion in particular has been the least studied alternative splicing
pattern. Recent work, however, has shown that intron retention
might be a conserved and more common mode of transcript
regulation than previously appreciated (Galante et al. 2004;
Braunschweig et al. 2014; Boutz et al. 2015; Mudvari et al.
2015; Wong et al. 2016), with examples found in hematopoiesis
(Wong et al. 2013; Edwards et al. 2016), T-cell activation (Ni et al.
2016), and neuronal development and activity (Bell et al. 2010;
Yang et al. 2012; Yap et al. 2012). Inappropriate intron retention
has also been identified in diverse genetic diseases, including
cancer (Seifert et al. 2006; Tanackovic et al. 2011; Dvinge and
Bradley 2015; Jung et al. 2015; Ortega-Recalde et al. 2015;
Kallabi et al. 2016). Although there are tools that can predict
the effects of sequence variants on alternative exon use or alter-
native 5′ donor or 3′ acceptor splice sites (Jian et al. 2014), to
our knowledge, there are no computational tools to predict in-
tron retention from sequence data. The increasingly appreciated
role of intron retention in normal physiology and disease there-
fore supports the need for empirical methods such as transcrip-
tomics to address this gap.
Intron retention may regulate normal gene expression or
cause disease not only by introducing additional protein sequence,
but also byNMDor by preventing export of the transcript from the
nucleus if the retained intron introduces a premature stop codon
(Ge and Porse 2014; Wong et al. 2016). The trend toward lower
DONSON levels inMMS samples suggests that the intron retention
leads to at least someNMD. Interestingly, in normal tissues, intron
6 ofDONSON is both less efficiently spliced out compared to other
introns and is variably spliced across tissues. This suggests that per-
haps, more generally, inefficiently spliced introns might be more
vulnerable to disruption by genetic mutation.
A nonconserved noncoding variant causing disease
Evolutionary conservation is often used to predict the likelihood of
variant pathogenicity. However, while DONSON is conserved
across all multicellular eukaryotes (Supplemental Fig. 5A,B), the
wild-type allele at the location of the MMS intronic mutation is
not well conserved (Supplemental Fig. 5A). This illustrates that
conservation analyses cannot be exclusively relied upon to predict
the clinical significance of noncoding variants.
DONSON is associated with genome replication complexes
disrupted in other microcephalic primordial dwarfisms
Clinically, MMS is a microcephalic primordial dwarfism, a class of
heterogeneous disorders characterized by prenatal and postnatal
growth restriction along with microcephaly (Klingseisen and
Jackson 2011; Khetarpal et al. 2016). MPD syndromes are classi-
fied into four types based on their clinical features and affected cel-
lular pathways, all of which are involved in some aspect of cell
cycle progression (Klingseisen and Jackson 2011; Fenwick et al.
2016; Khetarpal et al. 2016). Seckel syndrome is caused by muta-
tions in DNA damage response signaling and centriole biogenesis
factors (ATR, ATRIP, CEP152, CENPJ). Microcephalic osteodysplas-
tic primordial dwarfism (MOPD) type I/III is caused bymutation of
RNU4ATAC, a component of the minor spliceosome mediating
U12-intron splicing in many genes including some involved
in DNA replication. MOPD type II is caused by mutations in
PCNT encoding a key centrosomal protein. Meier-Gorlin syn-
drome (MGS) is caused by mutations in components of the prere-
plication and pre-initiation DNA replication complexes (ORC1,
ORC4,ORC6,CDT1,CDC6,GMNN,CDC45), which license replica-
tion origins and mediate loading and functioning of the replica-
tion fork helicase (Bicknell et al. 2011; Burrage et al. 2015;
Fenwick et al. 2016). Although MMS is distinct from these four
classic types of MPD syndromes, in this study we have presented
genetic, transcriptomic, and proteomic evidence linking MMS
and DONSON to other MPD syndromes, in particular, MGS.
Multiple independent lines of evidence strongly suggest
an essential role for DONSON in the same DNA prereplication
and replication fork complexes affected in MGS. First, expression
of both human DONSON and its fly ortholog Humpty Dumpty
(Hd) peaks in late G1 and S-phasewhen origins of replication com-
plexes assemble and genome replication takes place (Whitfield
et al. 2002; Bandura 2005; Bandura et al. 2005; Fuchs et al.
2010). Second, endogenous Hd localizes to the nucleus in foci
that overlap, though not exclusively, with origins of replication
(Bandura et al. 2005). Third, genetic loss of Hd in fly and siRNA
knockdown of human DONSON leads to impaired genome repli-
cation, arrest prior to or slowed progression through S-phase of
the cell cycle, and impaired cell proliferation (Bandura 2005;
Bandura et al. 2005; Fuchs et al. 2010). Hd andDONSONdepletion
also lead to an increase in histone variants marking DNA double-
strand breaks, which could be a consequence of stalled replication
forks (Bandura et al. 2005; Fuchs et al. 2010). Notably, Hd-null fly
mutants, which survive until the metamorphosis stage due to ma-
ternally supplied transcripts, have small brains and absent imagi-
nal discs (Bandura et al. 2005), the structures that give rise to the
legs, wings, antennae, and other external structures—a phenotype
reminiscent of MMS despite the vast phylogenetic distance be-
tween fly and human. Fourth, we identified numerous compo-
nents of the prereplication and replication fork complexes that
are highly co-expressed with DONSON in multiple species span-
ning from fly to human. Remarkably, our co-expression analysis
identified five of the seven known MGS genes (all except ORC2
and GMNN), and GMNN (geminin), which was not identified in
the co-expression analysis, is a genetic enhancer of the humpty
dumpty phenotype in fly double mutants (Bandura 2005). Fifth,
at the protein level Hd interacts with Asf1, a histone chaperone
associated with the MCM2-7 replication helicase.
Mechanistically, it is not unexpected that impaired genome
replication due to the reduction of DONSON leads to impaired cel-
lular proliferation and decreased overall growth, especially of or-
gans such as the brain whose development depends on a high
number of progenitor cellmitoses.DONSON is essential for normal
embryonic and fetal development and its complete absence is le-
thal, so the survivability of MMS is presumably due to the hypo-
morphic nature of its allele. Between two-thirds and ∼90% of
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DONSON transcripts are not properly spliced in MMS, suggesting
that additional MPD cases, particularly MGS-like syndromes,
might be caused by other DONSONmutations that are less severe.
Indeed, during review of this manuscript, Reynolds et al.
(2017) published a series of cases of recessive, hypomorphic muta-
tions in DONSON causing primary microcephaly, microcephaly
with short stature, and MPD. Most of the phenotypes they report
are nonlethal and milder than MMS, implying that the mutations
hadmilder effects on DONSON function than theMMSmutation.
However, they also reported one family (P21) from Saudi Arabia
that resembles the phenotype of MMS in the First Nations pop-
ulation and which, remarkably, contains the same homozygous
mutation, suggesting that a range of hypomorphic DONSON mu-
tations cause a wide spectrum of MPD and microcephalic syn-
dromes. Reynolds et al. (2017) further present extensive cell
biological evidence for an essential role for DONSON in the repli-
cation fork mediating genome replication. Altogether, the unique
MMS cases we have studied and the above related syndromes
define DONSON as a novel human disease gene and will help in-
form future investigations of its essential function in cellular rep-
lication and organismal development.
Methods
Human subjects and samples
All human studies were reviewed and approved by the Research
Ethics Committee of the University of Saskatchewan and the
Committee on Clinical Investigation of Boston Children’s
Hospital. The study was also supported throughout the project
by the Northern Medical Services of the University of
Saskatchewan and leaders of the local First Nations community.
See Supplemental Methods for further details. All samples in the
study are listed in Supplemental Data 1.
Linkage analysis
Multipoint parametric linkage analysis was performed using
Illumina Omni 2.5 SNP array data analyzed with Plink (Purcell
et al. 2007) andMerlin (Abecasis et al. 2002) under a recessivemod-
el. See Supplemental Methods for full details.
Genome sequencing
Targeted-capture sequencing was performed using a Roche
NimbleGen custom 385K capture array. Paired-end sequencing li-
braries were generated after capture and sequenced on an Illumina
sequencer.Whole-exome sequencing libraries were prepared using
the Sure-Select Human All Exon v2 kit (Agilent) and sequenced on
an Illumina sequencer.Whole-genome sequencingwas performed
by Complete Genomics. Targeted-capture and whole-exome data
were analyzedusingGATK (Vander Auwera et al. 2013).Whole-ge-
nome sequencing data were analyzed using Complete Genomics
software. Variants were annotated with ANNOVAR (Wang et al.
2010) and filtered if their allele frequency was ≥1% in any of the
following public variant databases: ExAC (Lek et al. 2016), 1000
Genomes Project (The 1000 Genomes Project Consortium 2015),
NHLBI Exome Sequencing Project (Tennessen et al. 2012), and
Complete Genomics 69 control genomes (Drmanac et al. 2010).
See Supplemental Methods for further details.
RNA sequencing
RNA-sequencing libraries were prepared with the Illumina TruSeq
Stranded mRNA kit and sequenced on HiSeq 2000 Illumina se-
quencers. Reads were aligned to the human reference genome
(GRCh38/hg38) with HISAT2 (Kim et al. 2015) using standard set-
tings. See Supplemental Methods for full details.
RT-PCR validation and relative splicing quantification
Residual DNA was eliminated from RNA samples using TURBO
DNA-free (Ambion), and cDNA was synthesized using oligo-dT
primers. RT-PCR was performed with primers in exon 6 and
exon 7, flanking intron 6. The exon 7 primer was labeled with
FAM to allow RT-PCR product quantification and calculation
of percentage unspliced product on a 3730 DNA Analyzer cap-
illary electrophoresis instrument (Applied Biosystems). See
Supplemental Methods for full details.
In situ hybridization in human and mouse embryos
Human embryo and fetus sections were obtained by the Joint
MRC/Wellcome Trust (Grant #099175/Z/12/Z) Human Develop-
mental Biology Resource (www.hdbr.org). In situ hybridization
probes were generated by PCR-cloning DONSON genomic se-
quence into plasmids for in vitro transcription with digoxigenin-
UTP. Hybridized probes were visualized using anti-digoxigenin al-
kaline phosphatase-conjugated antibody and NBT/BCIP (Roche).
Specificity of the in situ hybridization was confirmed with sense
probes. See Supplemental Methods for full method details.
Knockout mice
Mice heterozygous for a Donson knockout allele (Donsontm1a
(EUCOMM)Wtsi) were produced as part of the European Conditional
Mouse Mutagenesis Program (EUCOMM) and the International
Knockout Mouse Consortium and phenotyped at the Wellcome
Trust Sanger Institute. See Supplemental Methods for further
details.
siRNA knockdown and qPCR
cDNA of HeLa cells transfected with DONSON or GFP siRNA was
assayed using a qPCR panel of 91 cell cycle regulation genes
(Roche) on a LightCycler 480 instrument (Roche). cDNA of MMS
patient samples and controls was assayed using 18S rRNA and
DONSON TaqMan qPCR assays (Thermo Fisher). See Supplemental
Methods for full method details.
Data access
DNA and RNA sequencing data from this study (all samples except
HI-1400 and HI-2185) have been submitted to the NCBI Database
of Genotypes and Phenotypes (dbGaP; https://www.ncbi.nlm.nih.
gov/gap) under accession number phs000492.v2.p1. Data for
Autism Genetic Resource Exchange (AGRE) cell lines (HI-1400
and HI-2185) have been submitted to the AGRE data repository
(https://research.agre.org). Sanger sequencing from this study
has been submitted to the NCBI Trace Archive (https://trace.ncbi
.nlm.nih.gov/Traces/trace.cgi) under TI numbers 2344113440–
2344113468.
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